Karachi: S.G. Power Limited has announced a significant development for its shareholders with the signing of a Distribution Agreement with Lablink Enterprises, focusing on the distribution of Nipro hospital products within Pakistan. The announcement, made on July 8, 2026, marks a strategic move for S.G. Power Limited as it seeks to expand its footprint in the healthcare sector.

Nipro Corporation, a renowned entity in the global healthcare and medical technology landscape, is based in Osaka, Japan. With over seventy years of experience, Nipro is engaged in the development, manufacture, and supply of a wide array of medical devices, pharmaceutical products, and packaging solutions. Its products are distributed in over 150 countries, and the company is particularly noted for its expertise in hospital product infusion therapy, vascular, and other healthcare products.

Lablink Enterprises has been the exclusive distributor of Nipro hospital products in Pakistan for more than fifteen years, serving a vast network of leading hospitals, healthcare institutions, and clinical care providers across the nation.

According to information available from the Pakistan Stock Exchange (PSX), the agreement is a strategic initiative by S.G. Power Limited to leverage Nipro's globally recognized product portfolio with Lablink Enterprises' established distribution capabilities. This collaboration is poised to enhance S.G. Power's position in the medical devices sector in Pakistan, paving the way for future growth opportunities.

The company has assured its shareholders of further updates, complying with relevant regulatory requirements, as the partnership progresses. The move is part of S.G. Power's broader strategy to cement its presence in the healthcare industry, utilizing an experienced distribution platform to deliver Nipro's high-quality products to the Pakistani market.